infliximab | Ricerc@Sapienza

Sex differences in response to TNF-Inhibiting drugs in patients with spondyloarthropathies or inflammatory bowel diseases

Spondyloarthritis (SpA) and inflammatory bowel diseases (IBD) are chronic inflammatory diseases characterized by an aberrant immune response and inflammation with a key role for TNF in their pathogenesis. Accordingly, TNF-inhibiting therapy (TNFi) has dramatically improved the management of these diseases. However, about 30% of patients discontinue TNFi for lack of response, loss of response, and side effects and/or adverse events. Thus, the possibility to identify in advance those patients who will have a good response to TNFi would be extremely beneficial.

Lesson from epidemiology of paediatric Crohn's disease

Recent epidemiological evidences indicate a tremendous increase in incidence and prevalence of the chronic multifactorial non-communicable diseases (NCDs) in the western countries as well as in other geographical areas. These disorders result from an abnormal interplay between environment factors and host immunity, on a genetic susceptibility background.

Challenges in paediatric inflammatory bowel diseases in the COVID-19 time

Letter to the editor about of the outbreak of Coronavirus and the risks for children with inflammatory bowel disease

Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study

Background: Very few data regarding the use of infliximab in children with very early-onset inflammatory bowel disease (VEO-IBD) have been reported. Objective: We aimed to assess the efficacy and the safety of infliximab in children with VEO-IBD compared with older children. Methods: Children treated with infliximab were identified within the Italian IBD registry. The primary outcome was the rate of clinical remission at weeks 14 and 54. Secondary outcomes included the proportion of partial clinical response, treatment duration, and incidence of adverse events.

Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease

BACKGROUND AND AIMS:
Immunosuppressive therapy for inflammatory bowel disease (IBD) in pediatric patients is thought to increase the risk of malignancy and lymphoproliferative disorders, including hemophagocytic lymphohistiocytosis (HLH). We compared unadjusted incidence rates of malignancy and HLH in pediatric patients with IBD exposed to infliximab (IFX) with patients not exposed to biologics and calculated standardized incidence ratios (SIRs).